2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside (a salidroside analog) confers neuroprotection with a wide therapeutic window by regulating local glucose metabolism in a rat model of cerebral ischemic injury

Publication date: Available online 15 September 2018Source: NeuroscienceAuthor(s): Shu Yu, Hui Xu, Xiaojing Chi, Li Wei, Qiong Cheng, Yumin Yang, Chun Zhou, Fei DingAbstract2-(4-Methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-D-pyranoside (salidroside analog-4 g, SalA-4 g), has been shown neuroprotective prospects for the treatment of ischemic stroke. However, the dose-response and time window study for SalA-4 g, and the mechanism of SalA-4 g-mediated neuroprotection remain unclear. Here, we systematically investigated the therapeutic time window and dosage of SalA-4 g in permanent focal cerebral ischemia in rats. SalA-4 g dose-dependently improved stroke outcome. Either pre-treatment or post-treatment of SalA-4 g exhibited notable neuroprotection, and maintained for up to 6 h after ischemia onset. Moreover, significant neurological functional recovery was found after SalA-4 g administration in long-term functional assays. Further studies suggested that SalA-4 g ameliorated neuronal cell death, elevated local glucose metabolism and enhanced the expression level of glucose transporter 1 and 3 in the ipsilateral cortex and striatum. We suggest that data of this study is critical in exploring the clinical application prospects of SalA-4 g for the treatment of ischemic stroke.
Source: Neuroscience - Category: Neuroscience Source Type: research